keyword
https://read.qxmd.com/read/38492256/attitudes-toward-extended-release-naltrexone-treatment-for-opioid-use-disorder-among-african-americans
#1
JOURNAL ARTICLE
Khary K Rigg
BACKGROUND: Extended-release naltrexone (XR-NTX; Vivitrol®) is a long-acting injectable form of naltrexone, which is a medication used to treat opioid use disorder (OUD). In 2010, XR-NTX received Food and Drug Administration approval to treat OUD, becoming the first non-addictive and non-psychoactive medication for this condition. Because uptake of XR-NTX has been relatively low, less is known regarding how persons with OUD view this form of treatment. And because previous studies tend to rely on samples that lack racial diversity or are conducted outside the United States, we know very little about how African Americans view XR-NTX...
March 8, 2024: Drug and Alcohol Dependence
https://read.qxmd.com/read/38490723/a-statement-on-the-pharmacology-of-reinstatement-naltrexone-and-relapse-to-opioid-seeking
#2
JOURNAL ARTICLE
James E Barrett
No abstract text is available yet for this article.
March 15, 2024: Journal of Pharmacology and Experimental Therapeutics
https://read.qxmd.com/read/38485889/current-understanding-of-compulsive-sexual-behavior-disorder-and-co-occurring-conditions-what-clinicians-should-know-about-pharmacological-options
#3
REVIEW
Gemma Mestre-Bach, Marc N Potenza
Compulsive sexual behavior disorder (CSBD) has recently been recognized as a psychiatric disorder. Pharmacological treatments for CSBD have received little study and thus have limited empirical support. The main objective of the present work is to review existing literature on the efficacy of different drugs on the symptomatology of CSBD, including the subtype of problematic pornography use (PPU). The main pharmacological approaches to treating CSBD have included opioid antagonists (naltrexone and nalmefene), selective serotonin reuptake inhibitors (paroxetine, citalopram, fluoxetine, and sertraline), mood stabilizers (topiramate), tricyclic antidepressants (clomipramine), serotonin antagonist and reuptake inhibitors (nefazodone), and N-acetylcysteine...
March 14, 2024: CNS Drugs
https://read.qxmd.com/read/38481688/characterization-of-a-nonselective-opioid-receptor-functional-antagonist-implications-for-development-as-a-novel-opioid-dependence-medication
#4
JOURNAL ARTICLE
Siavash Shahbazi Nia, Yuma T Ortiz, Julio D Zuarth Gonzalez, Leila Shamir, Kofi Frimpong-Manson, Mohammad Anwar Hossain, Sadisna Shahi, Rayna Bandy, Anoushka Bhat, Dhavalkumar Patel, Hanin Diab, Jonathan Thompson, Lance R McMahon, Jenny L Wilkerson, Nadezhda A German
Opioids represent the most extensive category of abused substances in the United States, and the number of fatalities caused by these drugs exceeds those associated with all other drug overdoses combined. The administration of naltrexone, a potent pan-opioid receptor antagonist, to an individual dependent on opioids can trigger opioid withdrawal and induce severe side effects. There is a pressing demand for opioid antagonists free of opioid withdrawal effects. In our laboratory, we have identified a compound with affinity to mu, delta, and kappa opioid receptors in the range of 150-250 nM...
March 8, 2024: ACS Pharmacology & Translational Science
https://read.qxmd.com/read/38476879/multimodal-acute-pain-management-in-the-parturient-with-opioid-use-disorder-a-review
#5
REVIEW
Victor Koltenyuk, Ismat Mrad, Ian Choe, Mohamad Ibrahim Ayoub, Sangeeta Kumaraswami, Jeff L Xu
The opioid epidemic in the United States has led to an increasing number of pregnant patients with opioid use disorder (OUD) presenting to obstetric units. Caring for this complex patient population requires an interdisciplinary approach involving obstetricians, anesthesiologists, addiction medicine physicians, psychiatrists, and social workers. The management of acute pain in the parturient with OUD can be challenging due to several factors, including respiratory depression, opioid tolerance, and opioid-induced hyperalgesia...
2024: Journal of Pain Research
https://read.qxmd.com/read/38473137/effects-of-restraint-stress-on-circulating-corticosterone-and-met-enkephalin-in-chickens-induction-of-shifts-in-insulin-secretion-and-carbohydrate-metabolism
#6
JOURNAL ARTICLE
Colin G Scanes, Krystyna Pierzchała-Koziec, Alina Gajewska
This study examined the effects of acute restraint stress in the presence or absence of naltrexone on the circulating concentrations of insulin, glucose, Met-enkephalin and corticosterone in 14-week-old chickens [design: 2 sex × 2 stress/non-stress × 2 +/- naltrexone]. In chickens (five male and five females per treatment) subjected to restraint for 30 min, there were increases in the plasma concentrations of corticosterone and Met-enkephalin. The plasma concentrations of insulin and glucose were also increased in the chickens during restraint...
February 28, 2024: Animals: An Open Access Journal From MDPI
https://read.qxmd.com/read/38466214/in-brief-a-new-otc-naloxone-nasal-spray-rivive
#7
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
March 18, 2024: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/38453504/response-and-physiologic-outcomes-after-butorphanol-midazolam-and-medetomidine-immobilization-and-reversal-in-captive-reindeer-rangifer-tarandus
#8
JOURNAL ARTICLE
Lauren Ienello, Anne Rivas, Laura Martinelli, Adrienne Haley, Jessica Byrne, Erin Wendt-Hornickle
Sedation, recovery response, and physiologic outcomes were evaluated in five captive reindeer ( Rangifer tarandus ) in Minnesota using a completely reversible immobilization protocol. Reindeer were immobilized with butorphanol (0.23-0.32 mg/kg), midazolam (0.23-0.32 mg/kg), and medetomidine (0.15 mg/kg) (BMM) via IM dart. Induction time (IT), recumbency time (DT), and recovery time (RT) were recorded. Temperature (T), respiratory rate (RR), pulse rate (PR), pulse oximetry (SpO2 ), arterial blood gas values including oxygen (PaO2 ), and carbon dioxide (PaCO2 ) tensions and lactate (Lac) were recorded preoxygen supplementation and 15 min postoxygen supplementation...
March 2024: Journal of Zoo and Wildlife Medicine: Official Publication of the American Association of Zoo Veterinarians
https://read.qxmd.com/read/38445523/effects-of-dopamine-and-opioid-receptor-antagonism-on-the-neural-processing-of-social-and-nonsocial-rewards
#9
RANDOMIZED CONTROLLED TRIAL
Claudia Massaccesi, Sebastian Korb, Sebastian Götzendorfer, Emilio Chiappini, Matthaeus Willeit, Johan N Lundström, Christian Windischberger, Christoph Eisenegger, Giorgia Silani
Rewards are a broad category of stimuli inducing approach behavior to aid survival. Extensive evidence from animal research has shown that wanting (the motivation to pursue a reward) and liking (the pleasure associated with its consumption) are mostly regulated by dopaminergic and opioidergic activity in dedicated brain areas. However, less is known about the neuroanatomy of dopaminergic and opioidergic regulation of reward processing in humans, especially when considering different types of rewards (i.e., social and nonsocial)...
March 2024: Human Brain Mapping
https://read.qxmd.com/read/38432124/activation-of-epidermal-growth-factor-receptors-in-triple-negative-breast-cancer-cells-by-morphine-analysis-through-raman-spectroscopy-and-machine-learning
#10
JOURNAL ARTICLE
Gulay Sezer, Furkan Sahin, M Serdar Onses, Ahmet Cumaoglu
Triple negative breast cancer (TNBC) is a very aggressive form of breast cancer, and the analgesic drug morphine has been shown to promote the proliferation of TNBC cells. This article investigates whether morphine causes activation of epidermal growth factor receptors (EGFR), the roles of μ-opioid and EGFR receptors on TNBC cell proliferation and migration. While examining the changes with molecular techniques, we also aimed to investigate the analysis ability of Raman spectroscopy and machine learning-based approach...
February 27, 2024: Talanta
https://read.qxmd.com/read/38424567/quadruple-pharmacotherapy-for-alcohol-use-disorder-tolerable-yet-insufficient-a-case-report
#11
JOURNAL ARTICLE
Dale Terasaki, Aimee Ellinwood, Dan White
BACKGROUND: Combinations of alcohol use disorder (AUD) medications have been investigated, but few if any reports describe patients maintained on more than two options at the same time. CASE PRESENTATION: We report a case of a middle-aged man hospitalized with gastrointestinal bleeding and acute kidney injury who had been maintained on four AUD medications (naltrexone, acamprosate, disulfiram, and gabapentin) and multiple psychiatric medications simultaneously as an outpatient...
February 29, 2024: Substance Abuse Treatment, Prevention, and Policy
https://read.qxmd.com/read/38424347/pregnancy-rates-among-women-treated-with-medication-for-opioid-use-disorder
#12
JOURNAL ARTICLE
Jennifer K Bello, Kevin Y Xu, Joanne Salas, Bronwyn S Bedrick, Richard A Grucza
BACKGROUND: Treatment-seeking people with opioid use disorder (OUD) who are capable of pregnancy need accurate information about the potential impact of medication to treat OUD (MOUD) on fertility to make informed choices about treatment that are consistent with their reproductive wishes. There is a dearth of research on fertility associated with MOUD receipt in birthing people with OUD. OBJECTIVE: To estimate the association between treatment with MOUD and odds of conception among birthing people using national administrative claims...
February 29, 2024: Journal of General Internal Medicine
https://read.qxmd.com/read/38423262/burden-of-alcohol-use-and-inclusion-of-alcohol-use-disorder-medications-in-the-essential-medicine-lists-across-132-countries-an-observational-study
#13
JOURNAL ARTICLE
Arpit Parmar, Dinesh Prasad Sahu, Priyamadhaba Behera
Harmful use of alcohol effects the health of the population. The treatment coverage of alcohol use disorders (AUD) varies among countries. The study aimed to determine the inclusion of AUD medicines in various national Essential Medicine Lists (EMLs) and its association with alcohol consumption. It was a secondary data analysis of alcohol consumptions and AUD related medicines in EML. Data were extracted from the WHO Global Essential Medicines database and the WHO Global Status Report on Alcohol and Health 2018...
February 27, 2024: Alcohol
https://read.qxmd.com/read/38421578/pharmacological-and-non-pharmacological-approaches-for-the-management-of-neuropathic-pain-in-multiple-sclerosis
#14
REVIEW
Anastasiia D Shkodina, Mainak Bardhan, Hitesh Chopra, Onyekachi Emmanuel Anyagwa, Viktoriia A Pinchuk, Kateryna V Hryn, Anzhelina M Kryvchun, Dmytro I Boiko, Vinay Suresh, Amogh Verma, Mykhailo Yu Delva
Multiple sclerosis is a chronic inflammatory disease that affects the central nervous system and can cause various types of pain including ongoing extremity pain, Lhermitte's phenomenon, trigeminal neuralgia, and mixed pain. Neuropathic pain is a major concern for individuals with multiple sclerosis as it is directly linked to myelin damage in the central nervous system and the management of neuropathic pain in multiple sclerosis is challenging as the options available have limited efficacy and can cause unpleasant side effects...
February 29, 2024: CNS Drugs
https://read.qxmd.com/read/38421468/ivermectin-exerts-anticonvulsant-effects-against-status-epilepticus-induced-by-lithium-pilocarpine-in-rats-via-gaba-a-receptor-and-neuroinflammation-modulation-possible-interaction-of-opioidergic-pathways-and-k-atp-channel-with-nitrergic-system
#15
JOURNAL ARTICLE
Mohammad Amin Manavi, Samaneh Toutounchian, Sahar Afsahi, Zahra Ebrahim Soltani, Razieh Mohammad Jafari, Ahmad Reza Dehpour
Status epilepticus (SE) is a critical medical emergency marked by persistent or rapidly repeating seizures, posing a threat to life. Using the lithium-pilocarpine-induced SE model, we decide to evaluate the anti-seizure effects of ivermectin as a positive allosteric modulator of GABAA receptor and the underlying mechanisms involved. Lithium chloride was injected intraperitoneally at a dose of 127 mg/kg, followed by the administration of pilocarpine at a dose of 60 mg/kg after a 20-h interval in order to induce SE...
February 29, 2024: Molecular Neurobiology
https://read.qxmd.com/read/38419410/pharmacological-treatment-of-obesity-in-adults-in-norway-2004-2022
#16
JOURNAL ARTICLE
Paz Lopez-Doriga Ruiz, Øystein Karlstad, Kjersti Nøkleby, Kristina Slåtsve, Hanne L Gulseth, Haakon E Meyer, Kari Anne Sveen, Elisabeth Qvigstad, Kari Furu
AIMS: To describe trends in the use of anti-obesity drugs in Norway during the period 2004-2022. MATERIALS AND METHODS: We assessed the annual utilization of any available drug indicated for obesity recorded in the nationwide Norwegian Prescribed Drug Register for adults (age 18-79 years) from 1 January 2004 to 31 December 2022. Prevalence was stratified by sex and age group (18-29 years and 10-year age groups thereafter). Additional analyses were performed in individuals initiating treatment with an anti-obesity drug and on the cost of the anti-obesity drugs since 2017...
February 28, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38413972/-they-make-it-too-hard-and-too-many-hoops-to-jump-system-and-organizational-barriers-to-drug-treatment-during-epidemic-rates-of-opioid-overdose
#17
JOURNAL ARTICLE
Julia Dickson-Gomez, Sarah Krechel, Jessica Ohlrich, Helena Danielle Green Montaque, Margaret Weeks, Jianghong Li, Jennifer Havens, Antoinette Spector
INTRODUCTION: The United States is currently facing an opioid overdose crisis. Research suggests that multiple interventions are needed to reduce overdose deaths including increasing access and retention to medications to treat opioid use disorders (MOUD, i.e., methadone, buprenorphine, and naltrexone) and increasing the distribution and use of naloxone, a medication that can reverse the respiratory depression that occurs during opioid overdoses. However, barriers to MOUD initiation and retention persist and discontinuations of MOUD carry a heightened risk of overdose...
February 27, 2024: Harm Reduction Journal
https://read.qxmd.com/read/38408060/pilot-rct-comparing-low-dose-naltrexone-gabapentin-and-placebo-to-reduce-pain-among-people-with-hiv-with-alcohol-problems
#18
RANDOMIZED CONTROLLED TRIAL
Judith I Tsui, Sarah L Rossi, Debbie M Cheng, Sally Bendiks, Marina Vetrova, Elena Blokhina, Michael Winter, Natalia Gnatienko, Miroslav Backonja, Kendall Bryant, Evgeny Krupitsky, Jeffrey H Samet
BACKGROUND: To estimate the effects on pain of two medications (low-dose naltrexone and gabapentin) compared to placebo among people with HIV (PWH) with heavy alcohol use and chronic pain. METHODS: We conducted a pilot, randomized, double-blinded, 3-arm study of PWH with chronic pain and past-year heavy alcohol use in 2021. Participants were recruited in St. Petersburg, Russia, and randomized to receive daily low-dose naltrexone (4.5mg), gabapentin (up to 1800mg), or placebo...
2024: PloS One
https://read.qxmd.com/read/38405813/inflammatory-pain-resolution-by-mouse-serum-derived-small-extracellular-vesicles
#19
Zhucheng Lin, Xuan Luo, Jason R Wickman, Deepa Reddy, Richa Pande, Yuzhen Tian, Vivian Triana, Jingyun Lee, Cristina M Furdui, Desmond Pink, Ahmet Sacan, Seena K Ajit
Chronic pain is a significant public health issue. Current treatments have limited efficacy and significant side effects, warranting research on alternative strategies for pain management. One approach involves using small extracellular vesicles (sEVs) to transport beneficial biomolecular cargo to aid pain resolution. Exosomes are 30-150 nm sEVs that can carry RNAs, proteins, and lipid mediators to recipient cells via circulation. sEVs can be beneficial or harmful depending on their source and contents. To investigate the short and long-term effects of mouse serum-derived sEVs in pain modulation, sEVs from naive control or spared nerve injury (SNI) model donor mice were injected intrathecally into naive recipient mice...
February 18, 2024: bioRxiv
https://read.qxmd.com/read/38403887/comparative-costs-and-potential-affordability-of-a-multifaceted-intervention-to-improve-treatment-outcomes-among-people-with-hiv-who-inject-drugs-in-russia-economic-evaluation-of-the-linc-ii-randomized-controlled-trial
#20
JOURNAL ARTICLE
Sydney Rosen, Elena Blokhina, Ve Truong, Agata Bereznicka, Natalia Gnatienko, Emily Quinn, Dmitry Lioznov, Evgeny Krupitsky, Amy Michals, Karsten Lunze, Jeffrey H Samet
INTRODUCTION: The LINC-II randomized controlled trial in St. Petersburg, Russia for HIV-positive adults who inject drugs found that a multi-component intervention including initiation of antiretroviral therapy (ART) during admission to an addiction hospital, strengths-based case management and naltrexone significantly increased 12-month HIV viral suppression and ART retention. We conducted a comparative cost analysis to determine if the 12-month cost of the intervention is affordable within the current Russian health system...
February 2024: Journal of the International AIDS Society
keyword
keyword
5026
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.